AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JAN 10 - (NewsRx.com & NewsRx.net) -- Immunomedics, Inc., announced that its approved diagnostic imaging product for colorectal cancer, CEA-Scan (arcitumomab), was the subject of a presentation at the 24th Annual San Antonio Breast Cancer Symposium in December 2001.
The paper was authored by Dr. Joshua Rettig of the Arlington Cancer Center in Arlington, Texas.
In patients with suspected spread, or metastasis, of breast cancer, it is important to confirm the presence and location of these distant sites of disease. The study reported by Dr. Rettig involved 14 patients, 13 women and 1 man, with confirmed breast cancer and whose computed tomography (CT) findings did not show certain evidence of tumor metastases, although their blood values of carcinoembryonic antigen (CEA) were elevated, suggesting the disease had spread.
The Texas researcher found that combining the images made by CEA-Scan with those of spiral CT could improve the detection of breast cancer metastases. In this series of 14 patients, 15 additional sites of cancer were found by this combined imaging process in patients with a positive CT that did not change with time, and in four patients equivocal CT lesions could be confirmed by the CEA antibody imaging study.
"Since we knew that these patients were making more CEA by their tumors, we postulated that using a CEA imaging kit, such as CEA-Scan, may enable us to more precisely find sites of CEA-expressing breast cancer metastases, especially in patients whose CT ...